Lifecore Biomedical (NASDAQ:LFCR – Get Rating) and PaxMedica (NASDAQ:PXMD – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.
Profitability
This table compares Lifecore Biomedical and PaxMedica’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lifecore Biomedical | -40.38% | -21.34% | -7.21% |
| PaxMedica | N/A | N/A | -678.76% |
Analyst Ratings
This is a breakdown of recent recommendations for Lifecore Biomedical and PaxMedica, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lifecore Biomedical | 0 | 1 | 1 | 0 | 2.50 |
| PaxMedica | 0 | 0 | 0 | 0 | N/A |
Earnings and Valuation
This table compares Lifecore Biomedical and PaxMedica’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lifecore Biomedical | $182.86 million | 0.72 | -$114.68 million | ($2.50) | -1.74 |
| PaxMedica | N/A | N/A | -$14.80 million | ($1.30) | -1.12 |
PaxMedica has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.
Summary
PaxMedica beats Lifecore Biomedical on 5 of the 9 factors compared between the two stocks.
About Lifecore Biomedical
Lifecore Biomedical, Inc. engages in the design, development, manufacture, and sale of health and wellness products for food and biomaterials markets. It operates through the following segments: Lifecore, Curation Foods, and Others. The Lifecore segment sells products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans. The Curation Foods segment includes activities to market and pack specialty packaged whole and fresh-cut fruit and vegetables. The Other segment consists of corporate general and administrative expenses, non-Curation Foods and non-Lifecore interest income, and income tax expenses. The company was founded by Ray Stewart on October 31, 1986 and is headquartered in Santa Maria, CA.
About PaxMedica
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human African trypanosomiasis (HAT). It also develops PAX-102, an intranasal formulation of suramin for neurologic indications; and HAT-301 for the treatment of stage 1 East African HAT. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was founded in 2018 and is based in Tarrytown, New York.
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
